Merck today announced the launch of pivotal Phase 3 trials for four of its investigational drug candidates against hematological malignancies and solid tumors.

These global studies involve:
- Bomedemstat, being evaluated for the treatment of selected patients with essential thrombocythemia (ET);
- Nemtabrutinib, being evaluated for the treatment of selected patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL);
- MK-2870, under evaluation for certain patients with non-small cell lung cancer (NSCLC) and certain patients with previously treated endometrial carcinoma;
- MK-5684,under evaluation for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).

' These Phase 3 trial launches for four of our investigational candidates represent a critical milestone in our efforts to advance potential treatment options for people with solid tumors and hematological neoplasms and malignancies, ' said Dr. Marjorie Green, Senior Vice President and Head of Global Oncology Development at Merck Research Laboratories.

Copyright (c) 2024 CercleFinance.com. All rights reserved.